Endolumenal Surgical Platform

The intestine is a winding, contracting channel filled with body fluids and solids. Endoscopes and colonoscopes enable simple diagnostic procedures and the snaring of non-complex polyps. But they are free-floating inside the intestine and do not allow advanced therapies or surgical procedures. The ability to visualize polyps around flexures and behind folds in the colon is also limited with endoscopes. According to a recent study, up to 40% of all polyps in the intestine are not detected during standard colonoscopies.

The Endolumenal Surgical Platform (ESP) solves these challenges. ESP is mounted like a sleeve on a conventional endoscope and permits clinicians to:

  • Stabilize the endoscope tip in relation to the intestinal wall
  • Create a therapeutic zone™ with improved visualization inside the intestine
  • Manipulate the colon wall to provide better access for treatment

When used as a diagnostic tool, ESP will increase the polyp detection rate and make colonoscopy a more effective screening tool. It will also permit clinicians to perform simple surgical procedures with endoscopes, so that treatments can be done with no incisions, improved safety, and a faster recovery. ESP will be introduced at leading academic medical centers in a “first in human” clinical study in 2017 – the first step to widespread use at hospitals worldwide. Based on preclinical studies, ESP will have a major impact on digestive disease care.

Cost Savings

  • Improved patient outcomes and safety is the main motivation for endolumenal surgery, but cost savings is a close second:
  • The average cost of an open GI surgical procedure is $19,000, and the main cost driver is the average hospital stay of eight days.
  • For laparoscopic GI surgery, these figures are $15,300 and five days.
  • An ESP-based endolumenal surgery will have an average hospital stay of two days, with an average cost of $3,900. As endolumenal surgery becomes as accepted as endovascular care, hospital stays of one day will eventually become the norm. When the ESP family of products is implemented broadly, over $1.7 billion in cost savings will accrue to U.S. patients, hospitals, and insurers annually. Worldwide, the costs savings are estimated at more than $3.5 billion annually. Lumendi, Ltd. holds an exclusive worldwide license from Cornell University for the ESP platform and related ancillary products. Lumendi has a vision to revolutionize digestive surgery by developing and making available tools and devices that enable minimally invasive gastrointestinal interventions. The collaboration between MINT and Lumendi has opened up countless
    possibilities to transform digestive care for patients around the world. For more information, visit www.lumendi.com. Table 1 – ESP Cost Savings (U.S.)*

Target Applications Cases Where ESP Annual U.S. Cost

Would Be Used Savings ($M)**
Complex Polyps 52,000 $690
Anastomosis Leaks 25,600 $340
Volvulus 20,800 $276
Strictures 14,700 $195
Diverticular Disease 13,700 $182
Fistulae 2,800 $37
Total Annual Savings (U.S.) $1.7B
* Based on HCUP Data (Healthcare Cost and Utilization Project sponsored by the Agency for Healthcare
Research and Quality (AHRQ), Nationwide Inpatient Sample, 2011) and Medical Literature
** Assumes cost savings per procedure of $13,270 (averaging cost savings from open and from laparoscopic surgeries)

Flexible Articulating Surgical Tools

The Innovation Imperative Revolutions in health care do not happen overnight. It costs money to develop and test new tools and procedures. Philanthropic support is needed for continuing
medical education. These activities require an innovation ecosystem that draws on the talents of experts in many disciplines.

The MINT and CADC teams believe that convergence is the driving force of innovation. Our work involves surgeons, physicians, and medical educators from the departments
of Surgery, Medicine, and Radiology at Weill Cornell; and MBAs, engineers, life scientists, and physical scientists at MINT. Together, they are pushing the boundaries
of medicine, surgery, and patient care.

In the future:

  • Instead of removing a piece of intestine to treat Crohn’s disease, we will work within the intestine to insert a bio-absorbable stent with medicinal properties that widens the channel and cures inflammation.
  • Instead of resecting a length of intestine for diverticulitis, we will seal off the weakness with a new biomaterial, curing the disease and avoiding major surgery.
  • Instead of removing a major section of intestine for early colon cancer, we will locally resect the tumor, use advanced imaging techniques to stage it, and treat the cancer without the need for hospitalization.

This transformation is needed because the aging population, the growing incidence of digestive disease, and spiraling healthcare costs require it.

We are blazing a new trail of healing and discovery. We are pursuing innovation because patients deserve it.

Please join us in this effort.

To learn more or to discuss ways to contribute to the groundbreaking work of MINT, contact Matthew Baird at 212-746-2008 or mab9327@nyp.org.

Target Applications

$ 99

Per MonthComplex Polyps
Anastomosis Leaks
Diverticular Disease

Cases Where ESP Would Be Used

$ 99

Per Month52,000

Annual U.S. Cost Savings ($M)**

$ 99

Per Month$690